The formation of coronary collateral vessels is a compensatory mechanism secondary to repetitive or chronic myocardial ischemia. During the past three decades the functional and prognostic benefit of such collateral vessels has been established. There are large interindividual differences in the number and extent of collateral vessels that may be explained by differences in the anatomic situation or by differences in the individual capacity to develop functional collateral vessels. Diabetes mellitus has recently been identified as one of the first negative predictors of collateral vessel formation. Novel molecular approaches have helped to improve our understanding of the process of collateral vessel formation in recent years. Besides the process of true angiogenesis, i.e. the formation of new capillaries out of preexisting ones, the formation of a collateral circulation is largely based on the growth of preexisting arterioles (collateral vessels or anastomoses) named arteriogenesis. One important feature of arteriogenesis is the infiltration of monocytes into the growing collateral vessel. Our group shows that the ability of monocytes to migrate towards a gradient of VEGF-A is severely impaired in diabetic individuals, and this impaired response seems to be secondary to a signal transduction defect within the monocyte. In this review the pathophysiology of diabetes-related monocyte dysfunction and the potential role of VEGF-A in collateral vessel formation are discussed.
Coronary collateral vessel growth is an important
cance. It was found that patients with angiographically compensatory mechanism in advanced coronary artery documented coronary artery disease who develop collateral disease vessels had a higher prevalence of myocardial ischemia than those without collateral vessels indicating that the Coronary collateral vessels are of functional importance presence of myocardial ischemia is associated with the in patients with advanced coronary artery disease, if a growth of collateral vessels [6] . Fig. 1 shows an example coronary artery stenosis or occlusion is severe enough to of multiple collateral vessels secondary to an occlusion of cause repetitive or chronic regional myocardial ischemia the proximal LAD artery. It is interesting to note that these [1, 2] . Coronary collateral vessels are usually preformed, types of collateral vessels that connect the right with the but they need to grow in diameter to allow relevant left coronary artery were previously called 'anastomoses'; collateral blood flow [3, 4] , a process which is now called in contrast to real 'collateral vessels' that connect different arteriogenesis [5] . Clinical work from the past three segments within the same coronary artery. decades has convincingly shown that the presence and
The presence and extent of a coronary collateral circulaextent of existing collateral vessels is of functional signifition could be shown to be of prognostic relevance for the individual patient in terms of the outcome of a coronary event. The presence of adequate collateral vessels feeding collateral vessels in 205 coronary angiograms from diabetic patients with different severities of coronary artery disease and have compared them with the extent of collateral vessels in 205 coronary angiograms from nondiabetic patients with comparable other baseline characteristics.
There are several important implications and questions arising from this observation: (1) based on the functional and prognostic relevance of coronary collateral vessels, the reduced extent of a collateral circulation in diabetic individuals may contribute to their increased morbidity and mortality. (2) What are the mechanisms underlying reduced collateral vessel formation in diabetic individuals? (3) Knowledge about the molecular defect in diabetesassociated collateral vessel formation may be of importance for the development of therapeutic strategies to enhance collateral conductance. (4) The study by Abaci et el.
[14] is a descriptive one that did not evaluate the presence of recruitable collateral vessels. In addition, smaller-sized arteries remained undetected by angiography. Angiogenesis, defined as true capillary formation out of the myocardial area at risk may limit the infarct size preexisting ones, can only partly contribute to enhanced following coronary occlusion [7] and may even provide a tissue perfusion. Functional collateral vessels are formed survival benefit [6, [8] [9] [10] . Therefore, it is most important to out of preexisting ones by a process that is best described understand the functional basis of the process leading to by the term arteriogenesis [5] . Arteriogenesis describes collateral vessel formation. This is true for (i) predicting vascular growth in diameter, when arteries are created out the formation of coronary collateral vessels in patients with of small arterioles (Fig. 2 ). There are a number of cellular coronary artery disease and for (ii) tasks aiming in the processes that are necessary to allow an increase in therapeutic induction of collateral vessels (therapeutic vascular diameter including the proliferation of endothelial angiogenesis / therapeutic arteriogenesis). cells and smooth muscle cells. In addition, there is evidence that monocytes infiltrate growing arterioles during the process of arteriogenesis. Since the activation of 2. Coronary collateral vessel development is reduced monocytes using MCP-1 or LPS has been shown to in patients with diabetes mellitus promote arteriogenesis [15, 16] , it is likely that the various Diabetes mellitus is one of the most important cardiovascular risk factors that leads to vascular dysfunction and to the development of atherosclerotic disease. In fact, cardiac morbidity and mortality of patients with diabetes mellitus is greatly enhanced [11] . Diabetes mellitus causes endothelial dysfunction and thereby contributes to the development and progression of atherosclerosis including coronary artery disease [12] . In a functional context it is important to note that endothelial dysfunction can already be detected in young patients with early signs of insulin resistance independent of other classic cardiovascular risk factors [13] .
Last year it was shown for the first time that the cytokines and growth factors released by adhering and in the subacute phase of an acute myocardial infarction infiltrating monocytes are indirect stimulators of this [20] . In several in vivo studies of regional myocardial process (see below including Fig. 7) . Therefore, the ischemia, VEGF-A has been shown to be an inducer of recruitment of monocytes is crucial for the growth of enhanced collateral blood flow [21, 22] , although condicollateral vessels.
tions such as systemic application of VEGF-A had been Because arteriogenesis takes place in proximity to reported, where no increase in collateral blood flow could occluded vessels and because it is usually distant to areas be observed [23] . In all of these studies, however, the of tissue ischemia, shear stress is likely to be the most processes of monocyte migration in specific, and arrelevant initial driving force of this process [4] . Following teriogenesis in general, had not been assessed. There is the occlusion of a large artery, the hemodynamic situation clear experimental evidence, however, that the growth of changes and blood flow through preformed collateral collateral vessels is associated with the accumulation of arterioles rises. This leads to the activation of the endomonocytes in situ [16] . To close this gap, we have thelium within the arteriole and to the upregulation of established a test system for assessing monocyte migration adhesion molecules on the endothelial surface [17] , which as an important aspect of monocyte function. can trigger the invasion of monocytes into the wall of the growing collateral arteriole. This process is supported and potentiated by the action of several growth factors and 4. Monocyte function is severely affected in diabetic cytokines including VEGF-A, bFGF and MCP-1 which can patients stimulate monocyte migration. VEGF-A acts as a specific stimulus for monocyte migration, because monocytes
We have isolated peripheral blood monocytes from both express the VEGF-receptor1 / Flt-1 on their surface [18], a diabetic individuals (n516, mean age 68.3 years) and high-affinity receptor for VEGF-A [19] . In the case of non-diabetic individuals (n514) of similar age using VEGF-A, it has been shown that the invasion of monoficoll / percoll gradient centrifugation. The migratory recytes into some type of tumors seems Flt-1 tyrosine kinase sponse of monocyte preparations from healthy individuals (TK)-dependent, because this process of invasion is imcould be stimulated with VEGF-A (1 ng / ml) to about paired in Flt-1 TK2 / 2 mice (M. Shibuya, personal 150% of the unstimulated control in the modified Boyden communication). The function of the VEGF system in chamber. In contrast, monocyte preparations derived from monocytes is illustrated in Fig. 3 . There are several reasons diabetic individuals could not be stimulated with VEGF-A why VEGF-A might be a physiological inducer of monoat all [24] (Fig. 4) . There was still a migratory potential of cyte migration: VEGF-A serum levels are enhanced in a the monocytes from diabetic individuals, however, as the situation where collateral vessel formation is induced, i.e. tripeptide fMLP (fMetLeuPhe) could induce the activation of monocytes resulting in a G-protein-mediated migration that was not significantly impaired when compared with monocytes from normal controls (Fig. 4) . The migratory response of monocytes from diabetic individuals has not yet been assessed for other growth factors such as FGF-2. Given the importance of monocyte migration in the process of arteriogenesis that might be stimulated -at least in part -by VEGF-A, these data support the hypothesis that impaired monocyte migration might explain a reduced arteriogenic potential in diabetic hearts (Fig. 5 ).
Signal transduction defect as the molecular basis of impaired monocyte function in diabetic individuals
What is the exact nature of the migration defect of monocytes from diabetic individuals? We have initiated a search for identifying the molecular defect causing monocyte dysfunction. The first parameter we have tested was the function of VEGFR1 / Flt-1 using in-vitro-kinase assay, as very recently shown [24] . When assessing the pattern of responsible for the migratory signal [25] , no difference could be found between monocytes from diabetic individuals and those from healthy control subjects [24] (Fig.  6 ). We therefore conclude that the defect is downstream of VEGFR1 / Flt-1 and represents a signal transduction defect, i.e. the signal is blocked somewhere between the receptor and the cytoskeleton. At this stage, we can only speculate about the exact mechanism, because VEGF-induced signal transduction in monocytes is largely unknown. as assessed by immunoprecipitation with a phosphotyrosine-specific response can be explained by a signal transduction defect. Lack of antibody (4G10, UBI) and followed by in-vitro-kinase assay, SDS-PAGE VEGF-A-induced migration is likely to be associated with an impaired and autoradiography. The activation of the proteins p210, p120 and p69 arteriogenic response.
was quantitatively assessed using a PhosphorImager (Fuji).
Potential role of VEGF-A in stimulating
MCP-1 [28] that could further contribute to monocyte arteriogenesis -evidence from molecular cell biology recruitment. Finally, a third effect of VEGF-A on the endothelium is the induction of proliferation [19, 26] , Besides indicating impaired monocyte function, there is which should be a prerequisite for vascular growth as it a good basis for the assumption that -among other happens in arteriogenesis. molecules -VEGF-A might be actively involved in Monocytes infiltrating preformed collateral vessels repstimulating and promoting the process of arteriogenesis. resent a reservoir of peptide growth factors and cytokines The various actions of VEGF-A on endothelial cells and including VEGF-A, FGF-2, PDGF [29] , EGF, TNF-a, monocytes together with the fact that monocytes are MCP-1 and IL-1 (Fig. 2) . These molecules are released containing abundant amounts of VEGF-A support this from the monocytes / macrophages into the vessel wall. The assumption (Fig. 7) . Based on our current knowledge, exact functional significance of the various factors remains VEGF-A, Flt-1 (VEGF-R1) and KDR (VEGF-R2) are to be determined. However, VEGF-A and FGF-2 released important components involved in VEGF signalling all of from monocytes / macrophages can directly act on the which should be expressed in small arterioles and therefore endothelium (3 in Fig. 7 ), which they can do in a involved in growing collateral arteries. Flt-1 is expressed synergistic fashion if acting simultaneously [30] . Other both on endothelial cells and monocytes, while KDR is factors such as PDGF, but also FGF-2, can directly act on only expressed on endothelial cells [18] . It was recently smooth muscle cells and stimulate proliferation and migrashown that endothelial cells derived from human coronary tion. Some of these factors such as FGF-2 or PDGF-BB arteries express rather high levels of Flt-1 and KDR [26] .
can induce transcription, production and release of VEGF-VEGF-A could contribute to the process of ar-A from smooth muscle cells (4) [31] , that then can act as teriogenesis in a number of different ways as illustrated in described above (3). Fig. 7 . VEGF-A is a potent inducer of monocyte migration [18] (1). The migratory potency of VEGF-A is similar or even greater than the potency of MCP-1 on freshly isolated 7. Implications for therapeutic strategies using human monocytes (own, unpublished data). Because VEGF-A or other growth factors monocytes express only Flt-1 (VEGF-R1), some VEGFgene products cannot stimulate monocyte migration such
The proof of concept of therapeutic angiogenesis / theraas VEGF-C, VEGF-D and VEGF-E. There is a direct effect peutic arteriogenesis in regional myocardial or peripheral of VEGF-A on the endothelium (2) resulting in the ischemia has been done using young and healthy animals. upregulation of adhesion molecules such as ICAM-1 [27] ,
In fact there is evidence that old mice show a weaker which results in an increased adherence of monocytes to angiogenic response than do younger mice [32] . The the endothelium at this site. Another direct effect that has situation in human beings with manifest atherosclerosis is recently been suggested, is the induction and release of different. It remains to be shown whether functional collateral arteries can be induced in middle-aged or old patients. There is good evidence now, however, that the growth of vessels can in fact be induced using the peptide growth factor FGF-2 [33] . The fact that VEGF-A-induced monocyte migration -a potentially critical step in the process of collateral vessel formation -is severely impaired in diabetic individuals opens a new avenue of research, provides a novel insight into disease-related mechanisms and provides important information for the design of future trials aimed at the induction of collateral vessel formation. As diabetes mellitus is associated with an impairment of collateral vessel formation as well as an impairment of VEGF-A-induced monocyte function, it is likely that any treatment strategy vessel formation is unknown. However, there is evidence subjects with and without prior myocardial infarction. New Engl J from a rabbit model of angiogenesis that hypercholes- 
